Аннотация:
The production of the analgesic peptide HCRG21 for medical use is restricted by a number of limitations in the technology. The optimal biotechnological method scalable to industrial has been developed based on the production of a fusion protein containing a special leader, His-tag, and Smt3 sequence upstream in the peptide sequence. The resulting peptide shared its inhibitory activity to TRPV1 ion channel identical to the published early.
Ключевые слова:
analgesic peptide, biotechnology, SUMO fusion, production in prokaryotes, fluorescence imaging, TRPV1 ion channel.
Образец цитирования:
M. N. Tereshin, A. M. Komyakova, V. N. Stepanenko, I. V. Myagkikh, N. S. Shoshina, Yu. V. Korolkova, E. V. Leychenko, S. A. Kozlov, “Optimized method for the recombinant production of a sea anemone’s peptide”, Mendeleev Commun., 32:6 (2022), 745–746
Образцы ссылок на эту страницу:
https://www.mathnet.ru/rus/mendc785
https://www.mathnet.ru/rus/mendc/v32/i6/p745
Эта публикация цитируется в следующих 2 статьяx:
O. V. Sintsova, N. A. Priymenko, M. M. Garbuz, A. A. Klimovich, N. A. Shved, A. S. Menshov, S. D. Anastyuk, M. P. Isaeva, I. N. Gladkikh, E. V. Leychenko, “Efficient recombinant production of RpII, a NaV-modulating peptide from the sea anemone Heteractis magnifica”, Mendeleev Commun., 34:1 (2024), 15–17
Elena Efremenko, Aysel Aslanli, Ilya Lyagin, “Advanced Situation with Recombinant Toxins: Diversity, Production and Application Purposes”, IJMS, 24:5 (2023), 4630
Обратная связь: